Identificador persistente para citar o vincular este elemento: http://hdl.handle.net/10553/76409
Campo DC Valoridioma
dc.contributor.authorMorales, Jesus R.en_US
dc.contributor.authorHurtado, Oliviaen_US
dc.contributor.authorBallesteros, Ivanen_US
dc.contributor.authorVivancos, Joseen_US
dc.contributor.authorNombela, Florentinoen_US
dc.contributor.authorLizasoain, Ignacioen_US
dc.contributor.authorCastrillo Viguera, Antonio Jesúsen_US
dc.contributor.authorMoro, Maria A.en_US
dc.date.accessioned2020-12-07T13:08:27Z-
dc.date.available2020-12-07T13:08:27Z-
dc.date.issued2008en_US
dc.identifier.issn0039-2499en_US
dc.identifier.otherWoS-
dc.identifier.urihttp://hdl.handle.net/10553/76409-
dc.description.abstractBackground and purpose: Liver X receptors (LXR ) and (LXR ), also known asNR1H3andNR1H2, respectively, are ligand-activated transcription factors that belong to the nuclearreceptor superfamily. Recent work has also identified LXRs as potent anti-inflammatorymolecules in macrophages and other immune cells. We have explored the endogenous role ofLXR receptors in acute stroke with genetic loss of LXR function by using LXR , -/- mice.Methods: Experimental ischemia was carried out by middle cerebral artery occlusion (MCAO)in wild type controls and Nr1h3-/-Nr1h2-/-double mutant (LXR , -/-) mice on a Sv129/C57BL/6background, obtained through a collaboration with Drs. David Mangelsdorf and Peter Tontonoz.Infarct size was determined by 2,3,5-triphenyltetrazolium chloride (TTC) staining. The effect ofexogenous LXR activation was studied by administration of the LXR agonists GW3965 (20mg/kg) 10 min after the ischemic occlusion. Neurological assesment was performed aspreviously described (Caso et al. Circulation 2007).Results: Administration of GW3965 reducedinfarct lesion in WT animals, whereas no significant changes were observed in LXR-deficientmice under the same experimental conditions. Interestingly, larger infarcted areas wereobserved in mice lacking both LXR isoforms when compared to control mice. Moreover, whenthe neurological test was applied to this set of mice, lower scores demonstrated a protectiveaction in WT mice treated with GW compound, whereas LXR , -/- mice showed poorneurological statusConclusion: These data show that an endogenous LXR activatory pathwayduring experimental stroke mediates a potent and natural protection, which could be causedby physiological LXR agonists such as oxysterols. This evidence also suggests that levels ofendogenous LXR agonists might serve as prognostic markers in stroke patients.en_US
dc.languageengen_US
dc.relation.ispartofStrokeen_US
dc.sourceStroke[ISSN 0039-2499],v. 39 (2), p. 662, Abstract P381, (Febrero 2008)en_US
dc.subject3210 Medicina preventivaen_US
dc.subject320507 Neurologíaen_US
dc.subject.otherLiver X receptorsen_US
dc.subject.otherLXRen_US
dc.subject.otherAntiinflammatory moleculesen_US
dc.titleLXR receptors mediate endogenous neuroprotection in acute experimental strokeen_US
dc.typeinfo:eu-repo/semantics/conferenceObjecten_US
dc.typeConferenceObjecten_US
dc.relation.conference33rd International Stroke Conferenceen_US
dc.identifier.isi000252726100594-
dc.description.lastpage662en_US
dc.identifier.issue2-
dc.description.firstpage662en_US
dc.relation.volume39en_US
dc.investigacionCiencias de la Saluden_US
dc.type2Actas de congresosen_US
dc.contributor.daisngid2796130-
dc.contributor.daisngid598463-
dc.contributor.daisngid1805777-
dc.contributor.daisngid99440-
dc.contributor.daisngid1064642-
dc.contributor.daisngid109190-
dc.contributor.daisngid225640-
dc.contributor.daisngid681244-
dc.description.numberofpages1en_US
dc.utils.revisionen_US
dc.contributor.wosstandardWOS:Morales, JR-
dc.contributor.wosstandardWOS:Hurtado, O-
dc.contributor.wosstandardWOS:Ballesteros, I-
dc.contributor.wosstandardWOS:Vivancos, J-
dc.contributor.wosstandardWOS:Nombela, F-
dc.contributor.wosstandardWOS:Lizasoain, I-
dc.contributor.wosstandardWOS:Castrillo, A-
dc.contributor.wosstandardWOS:Moro, MA-
dc.date.coverdateFebrero 2008en_US
dc.identifier.abstractidP381-
dc.identifier.conferenceidevents120603-
dc.identifier.ulpgcen_US
dc.contributor.buulpgcBU-DERen_US
dc.description.jcr6,499
dc.description.jcrqQ1
dc.description.scieSCIE
item.grantfulltextnone-
item.fulltextSin texto completo-
crisitem.event.eventsstartdate19-02-2008-
crisitem.event.eventsenddate21-02-2008-
crisitem.author.deptGIR IUIBS: Farmacología Molecular y Traslacional-
crisitem.author.deptIU de Investigaciones Biomédicas y Sanitarias-
crisitem.author.orcid0000-0002-2057-2159-
crisitem.author.parentorgIU de Investigaciones Biomédicas y Sanitarias-
crisitem.author.fullNameCastrillo Viguera, Antonio Jesús-
Colección:Actas de congresos
Vista resumida

Google ScholarTM

Verifica


Comparte



Exporta metadatos



Los elementos en ULPGC accedaCRIS están protegidos por derechos de autor con todos los derechos reservados, a menos que se indique lo contrario.